Zinforo

Zinforo

ceftaroline fosamil

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ceftaroline fosamil
Indications/Uses
Community-acquired pneumonia (CAP) & complicated skin & soft tissue infections (cSSTI) in neonates, infants, childn, adolescents & adults.
Dosage/Direction for Use
IV infusion CAP & cSSTI Adult & adolescent 12 to <18 yr, ≥33 kg 600 mg over 5-60 min every 12 hr. CrCl >30 to ≤50 mL/min 400 mg over 5-60 min every 12 hr, ≥15 to ≤30 mL/min 300 mg over 5-60 min every 12 hr, ESRD including haemodialysis 200 mg over 5-60 min every 12 hr. Adolescent 12 to <18 yr, <33 kg & childn ≥2 to <12 yr 12 mg/kg to max: 400 mg over 5-60 min every 8 hr. CrCl >30 to ≤50 mL/min 8 mg/kg to max: 300 mg over 5-60 min every 8 hr, ≥15 to ≤30 mL/min 6 mg/kg to max: 200 mg over 5-60 min every 8 hr. Infant ≥2 mth to <2 yr 8 mg/kg over 5-60 min every 8 hr. Birth to <2 mth 6 mg/kg over 5-60 min every 8 hr. cSSTI confirmed or suspected to be caused by S. aureus w/ MIC=2 or 4 mg/L to ceftaroline Adult 600 mg over 120 min every 8 hr. CrCl >30 to ≤50 mL/min 400 mg over 120 min every 8 hr, ≥15 to ≤30 mL/min 300 mg over 120 min every 8 hr, ESRD including haemodialysis 200 mg over 120 min every 8 hr. Adolescent & childn ≥2 yr to <18 yr 12 mg/kg to max: 600 mg over 120 min every 8 hr. CrCl >30 to ≤50 mL/min 10 mg/kg to max: 400 mg over 120 min every 8 hr, ≥15 to ≤30 mL/min 8 mg/kg to max: 300 mg over 120 min every 8 hr. Infant ≥2 mth to <2 yr 10 mg/kg over 120 min every 8 hr. Duration of treatment: CAP 5-7 days. cSSTI 5-14 days.
Contraindications
Hypersensitivity to ceftaroline fosamil, cephalosporins & other β-lactam antibiotics eg, penicillins or carbapenems.
Special Precautions
Discontinue use if hypersensitivity & severe cutaneous ARs eg, SJS, TEN, DRESS, acute generalised exanthematous pustulosis occur. Clostridium difficile-associated diarrhoea; antibacterial-associated & pseudomembranous colitis; pre-existing seizure disorder; superinfection. Patients w/ severe sepsis/septic shock, severe underlying lung disease (eg, cystic fibrosis), PORT risk class V, CAP requiring ventilation at presentation, CAP due to methicillin-resistant S aureus or patients requiring intensive care; necrotizing fasciitis, perirectal abscess, patients w/ 3rd-degree & extensive burns; diabetic foot infections. Immunocompromised patients. Development of +ve direct antiglobulin test. May affect ability to drive & use machines. Not to be used during pregnancy. Not recommended during lactation.
Adverse Reactions
Positive Coombs' direct test. Headache, dizziness; phlebitis; diarrhoea, nausea, vomiting, abdominal pain; increased transaminases; rash, pruritus; infusion site erythema, phlebitis & pain, pyrexia.
MIMS Class
Cephalosporins
ATC Classification
J01DI02 - ceftaroline fosamil ; Belongs to the class of other cephalosporins and penems. Used in the systemic treatment of infections.
Presentation/Packing
Form
Zinforo powd for infusion (vial) 600 mg
Packing/Price
10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in